DRIVEN TO CREATE NOVEL THERAPEUTICS TO TREAT AND PREVENT METASTASIS OF CANCER
MetasTx is creating treatments that prevent and treat prostate cancer metastasis without the devastating effects of today’s Androgen deprivation therapies.
First In Class Treatment Saves and Improves Lives
The scientific foundation of MetasTx’s breakthrough work is based on decades of research focused on p21 activated kinase (PAK-1). This enzyme is well-known to be pivotal in cancer initiation and metastasis and is highly expressed in Prostate, Breast, and Skin cancers.
MetasTx is developing a pipeline of novel cancer agents targeted at specific solid tumors based on advances in the delivery of IPA-3, a highly selective inhibitor of Group-1 P21 activated kinases (PAK).
An estimated 608,570 Americans died from cancer in 2021. The five-year survival rate of metastatic cancers, those that travel from the primary site to a distant site (also known as Stage 4 or 5), is approximately 30%.
This area of research is ripe for advances. Unfortunately, current drug discovery in metastatic cancer has not resulted in therapies with significant increases in patient survival, specificity in drug delivery, or mitigation of deleterious side effects; Until now.
MetasTx Improves Efficacy In Prostate Cancer Treatment
MetasTx successfully concluded studies revealing the integral role of PAK1 in the regulation of epithelial-to-mesenchymal transition (EMT), a process necessary for early cancer cells to switch to metastatic ones. The stability and efficacy of MTX-101 are significantly superior in inhibiting prostate tumor growth and metastasis in various mouse models of prostate cancer and demonstrate broad applicability across solid tumor cancers.
TESTIMONIAL
“A drug that can modulate metastases without depleting testosterone is a HOME RUN.”
Dr. Elizabeth Heath
Hartmann Endowed Chair for Prostate Cancer Research; Director of Prostate Cancer Research at Karmanos Cancer Institute, Wayne University School of Medicine; Chair, Genitourinary Oncology Multidisciplinary Team; Professor of Oncology and Medicine; Associate Center Director, Translational Sciences
